JP2022548472A5 - - Google Patents

Info

Publication number
JP2022548472A5
JP2022548472A5 JP2022506595A JP2022506595A JP2022548472A5 JP 2022548472 A5 JP2022548472 A5 JP 2022548472A5 JP 2022506595 A JP2022506595 A JP 2022506595A JP 2022506595 A JP2022506595 A JP 2022506595A JP 2022548472 A5 JP2022548472 A5 JP 2022548472A5
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
amino acids
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022506595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548472A (ja
JP7756072B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/051255 external-priority patent/WO2021055594A1/en
Publication of JP2022548472A publication Critical patent/JP2022548472A/ja
Publication of JP2022548472A5 publication Critical patent/JP2022548472A5/ja
Application granted granted Critical
Publication of JP7756072B2 publication Critical patent/JP7756072B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022506595A 2019-09-20 2020-09-17 T細胞調節ポリペプチド及びその使用方法 Active JP7756072B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962903441P 2019-09-20 2019-09-20
US62/903,441 2019-09-20
US202062990693P 2020-03-17 2020-03-17
US62/990,693 2020-03-17
US202063048561P 2020-07-06 2020-07-06
US63/048,561 2020-07-06
PCT/US2020/051255 WO2021055594A1 (en) 2019-09-20 2020-09-17 T-cell modulatory polypeptides and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022548472A JP2022548472A (ja) 2022-11-21
JP2022548472A5 true JP2022548472A5 (enExample) 2023-09-25
JP7756072B2 JP7756072B2 (ja) 2025-10-17

Family

ID=74884186

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022506595A Active JP7756072B2 (ja) 2019-09-20 2020-09-17 T細胞調節ポリペプチド及びその使用方法

Country Status (11)

Country Link
US (2) US20220143063A1 (enExample)
EP (1) EP4030897A4 (enExample)
JP (1) JP7756072B2 (enExample)
KR (1) KR20220066075A (enExample)
CN (1) CN114423284A (enExample)
AU (1) AU2020348373A1 (enExample)
CA (1) CA3146591A1 (enExample)
IL (1) IL290635A (enExample)
MX (1) MX2022003367A (enExample)
TW (1) TW202126683A (enExample)
WO (1) WO2021055594A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ,インコーポレーテッド コンジュゲーション部位を有するt細胞調節多量体ポリペプチド及びその使用方法
TWI856047B (zh) * 2018-12-19 2024-09-21 美商信號生物製藥公司 多聚體t細胞調節多肽及其使用方法
US12453774B2 (en) * 2019-11-07 2025-10-28 Genoimmune Therapeutics Co., Ltd. Tumor immunotherapy polypeptide and application thereof
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
US12275766B2 (en) * 2020-12-23 2025-04-15 Janssen Biotech, Inc. Neoantigen peptide mimics
AU2022238389A1 (en) * 2021-03-19 2023-10-05 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
JP2025511703A (ja) * 2022-04-07 2025-04-16 キュー バイオファーマ, インコーポレイテッド 免疫細胞結合ポリペプチド
CN115820736B (zh) * 2022-12-08 2024-05-10 西南大学 家蚕丝胶蛋白Ser4在提高蚕丝性能中的应用及其方法
WO2024264004A2 (en) * 2023-06-23 2024-12-26 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
WO2024264007A2 (en) * 2023-06-23 2024-12-26 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195531A2 (en) * 2014-06-18 2015-12-23 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
WO2016154246A1 (en) * 2015-03-23 2016-09-29 The Johns Hopkins University Hla-restricted epitopes encoded by somatically mutated genes
AU2017213117A1 (en) * 2016-01-27 2018-07-19 CSL Behring Lengnau AG Recombinant IgG Fc multimers
WO2017151818A2 (en) * 2016-03-02 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CA3014466A1 (en) * 2016-03-03 2017-09-08 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2017201210A1 (en) * 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
ES2973548T3 (es) * 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
EP3565829A4 (en) * 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
US20200010528A1 (en) * 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
JP2020534352A (ja) * 2017-09-07 2020-11-26 キュー バイオファーマ,インコーポレーテッド コンジュゲーション部位を有するt細胞調節多量体ポリペプチド及びその使用方法
CN111886241A (zh) * 2018-01-09 2020-11-03 库尔生物制药有限公司 多聚体t细胞调节多肽及其使用方法
JP7153287B2 (ja) * 2020-05-12 2022-10-14 住友ファーマ株式会社 癌を処置するための医薬組成物

Similar Documents

Publication Publication Date Title
JP2022548472A5 (enExample)
JP2022534846A5 (enExample)
JP2020514375A5 (enExample)
CA3089333C (en) Anti-pdl1, il-15 and tgf-beta receptor combination molecules
KR102457731B1 (ko) 병용 약학 조성물
JP2018525006A5 (enExample)
JP2024512470A5 (enExample)
JP2020511949A5 (enExample)
JP2021500855A5 (enExample)
IL308851B1 (en) T cell modulatory multimeric polypeptides and methods of using them
JP2023526723A5 (enExample)
CN117986384A (zh) 与il-12和il-18的基于il-15的融合物
JP2017519491A5 (enExample)
JP7783164B2 (ja) 改変インターロイキン2受容体ベータアゴニスト
JP2021522835A (ja) 二機能性結合ポリペプチド
CN116981470A (zh) T细胞调节多肽和其使用方法
US20230414777A1 (en) Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
JP2022515331A5 (enExample)
US11484572B2 (en) Use of HLA-B27 homodimers for cancer treatment
BR112021011838A2 (pt) Peptídeos multiméricos moduladores de células t e métodos de uso destes
WO2022125694A1 (en) Fusions of interleukin polypeptides with bispecific antigen binding molecules for modulating immune cell function
JP7313017B2 (ja) MHCクラスIaオープンコンフォーマー
JP2024541334A5 (enExample)
JP2024537096A (ja) がんの治療のための代替的なPD1-IL7vイムノコンジュゲート
WO2020232365A1 (en) Nk cell-directed chimeric proteins